There is an erratum for this publication.

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Erstveröffentlichung
2020
Authors
Kroschinsky, Frank
Middeke, Jan Moritz
Janz, Martin
Lenz, Georg
Witzens-Harig, Mathias
et al.
Wissenschaftlicher Artikel


Published in
Investigational New Drugs. - : Springer, 2020. - ISSN 0167-6997. - eISSN 1573-0646
Link to publication
https://dx.doi.org/10.1007/s10637-020-00916-3
Institutions
UKU. Klinik für Innere Medizin III
Subject headings
[Free subject headings]: BI 836826 | CD37 | Diffuse large B cell lymphoma | Non-Hodgkin lymphoma | Phase I | Relapsed | MONOCLONAL-ANTIBODY | TETRASPANIN | EXPRESSION | PROTEIN
[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item record